Moderna, Inc. (MRNA) has a negative trailing P/E of -7.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 19.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -14.00%, forward earnings yield 5.10%.
Criteria proven by this page:
Overall SharesGrow Score: 42/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -5.5 | 0.00 | 1.42 | 11.00 | 0.05% |
| 2017 | -27.3 | 0.34 | 11.18 | 33.98 | 0.02% |
| 2018 | -13.1 | -0.21 | 3.28 | 37.17 | - |
| 2019 | -12.6 | -0.39 | 5.51 | 107.47 | - |
| 2020 | -53.3 | -2.02 | 15.56 | 49.59 | - |
| 2021 | 8.4 | -0.01 | 7.24 | 5.77 | - |
| 2022 | 8.5 | -0.28 | 3.70 | 3.75 | - |
| 2023 | -8.1 | 0.05 | 2.74 | 5.55 | - |
| 2024 | -4.5 | 0.18 | 1.46 | 4.99 | - |
| 2025 | -4.1 | 0.19 | 1.33 | 5.90 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.58 | $101.54M | $-216.21M | -212.9% |
| 2017 | $-0.68 | $176.97M | $-255.92M | -144.6% |
| 2018 | $-4.74 | $122.51M | $-384.73M | -314% |
| 2019 | $-1.55 | $48.04M | $-514.02M | -1070.1% |
| 2020 | $-1.96 | $274.49M | $-747.06M | -272.2% |
| 2021 | $28.31 | $17.74B | $12.2B | 68.8% |
| 2022 | $20.10 | $19.26B | $8.36B | 43.4% |
| 2023 | $-12.34 | $6.85B | $-4.71B | -68.8% |
| 2024 | $-9.27 | $3.24B | $-3.56B | -110% |
| 2025 | $-7.26 | $1.94B | $-2.82B | -145.2% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-6.39 | $-8.49 – $-4.79 | $2.08B | $1.94B – $2.22B | 16 |
| 2027 | $-4.59 | $-6.10 – $-0.11 | $2.5B | $1.84B – $4.31B | 15 |
| 2028 | $-2.90 | $-6.17 – $0.69 | $3.15B | $3.12B – $3.18B | 15 |
| 2029 | $-0.03 | $-0.05 – $-0.02 | $5.01B | $4.02B – $7.46B | 10 |
| 2030 | $2.66 | $1.98 – $4.35 | $6.64B | $5.33B – $9.89B | 6 |
